{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:48:03Z","timestamp":1787068083030,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11033-023-08432-2","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T06:02:26Z","timestamp":1682488946000},"page":"5105-5115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An association of epidermal growth factor receptor mutation subtypes with prognostic prediction and site-specific recurrence in advanced stage lung cancer patients"],"prefix":"10.1007","volume":"50","author":[{"given":"Jigna","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apexa","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomi","family":"Tarapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitarth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunayna","family":"Bhavnagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-2839","authenticated-orcid":false,"given":"Franky D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"3","key":"8432_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8432_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11\u201330. https:\/\/doi.org\/10.3322\/caac.21166","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"8432_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS et al (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14(8):535\u2013546. https:\/\/doi.org\/10.1038\/nrc3775","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"8432_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJMoa050736","volume":"353","author":"MS Tsao","year":"2005","unstructured":"Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353(2):133\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa050736","journal-title":"N Engl J Med"},{"issue":"25","key":"8432_CR5","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","volume":"368","author":"AT Shaw","year":"2013","unstructured":"Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385\u20132394. https:\/\/doi.org\/10.1056\/NEJMoa1214886","journal-title":"N Engl J Med"},{"issue":"19","key":"8432_CR6","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311(19):1998\u20132006. https:\/\/doi.org\/10.1001\/jama.2014.3741","journal-title":"JAMA"},{"issue":"5","key":"8432_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.bcp.2010.05.014","volume":"80","author":"T Yoshida","year":"2010","unstructured":"Yoshida T, Zhang G, Haura EB (2010) Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Biochem Pharmacol 80(5):613\u2013623. https:\/\/doi.org\/10.1016\/j.bcp.2010.05.014","journal-title":"Biochem Pharmacol"},{"issue":"14","key":"8432_CR8","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","volume":"23","author":"PA Janne","year":"2005","unstructured":"Janne PA, Engelman JA, Johnson BE (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23(14):3227\u20133234. https:\/\/doi.org\/10.1200\/JCO.2005.09.985","journal-title":"J Clin Oncol"},{"issue":"2","key":"8432_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1517\/14712598.2012.748742","volume":"13","author":"Y Wang","year":"2013","unstructured":"Wang Y, Deng G, Liu X et al (2013) Monoclonal antibodies in lung cancer. Expert Opin Biol Ther 13(2):209\u2013226. https:\/\/doi.org\/10.1517\/14712598.2012.748742","journal-title":"Expert Opin Biol Ther"},{"key":"8432_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fphar.2013.00053","volume":"4","author":"R Perez","year":"2013","unstructured":"Perez R, Crombet T, de Leon J et al (2013) A view on EGFR-targeted therapies from the oncogene-addiction perspective. Front Pharmacol 4:53. https:\/\/doi.org\/10.3389\/fphar.2013.00053","journal-title":"Front Pharmacol"},{"issue":"1","key":"8432_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ctrv.2013.06.002","volume":"40","author":"J Remon","year":"2014","unstructured":"Remon J, Moran T, Majem M et al (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev 40(1):93\u2013101. https:\/\/doi.org\/10.1016\/j.ctrv.2013.06.002","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"8432_CR12","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1158\/1078-0432.CCR-13-2437","volume":"20","author":"HA Yu","year":"2014","unstructured":"Yu HA, Riely GJ, Lovly CM (2014) Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors. Clin Cancer Res 20(23):5898\u20135907. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2437","journal-title":"Clin Cancer Res"},{"issue":"21","key":"8432_CR13","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"5676","key":"8432_CR14","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497\u20131500. https:\/\/doi.org\/10.1126\/science.1099314","journal-title":"Science"},{"issue":"9","key":"8432_CR15","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/cas.12996","volume":"107","author":"Y Kobayashi","year":"2016","unstructured":"Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 107(9):1179\u20131186. https:\/\/doi.org\/10.1111\/cas.12996","journal-title":"Cancer Sci"},{"issue":"10","key":"8432_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"issue":"2","key":"8432_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213\u2013222. https:\/\/doi.org\/10.1016\/S1470-2045(13)70604-1","journal-title":"Lancet Oncol"},{"issue":"5","key":"8432_CR18","first-page":"411","volume":"4","author":"Y Lin","year":"2014","unstructured":"Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4(5):411\u2013435","journal-title":"Am J Cancer Res"},{"issue":"10","key":"8432_CR19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1158\/1078-0432.CCR-14-3154","volume":"21","author":"GJ Riely","year":"2015","unstructured":"Riely GJ, Yu HA (2015) EGFR: the paradigm of an Oncogene-Driven lung cancer. Clin Cancer Res 21(10):2221\u20132226. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3154","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8432_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12291-019-00864-7","volume":"36","author":"J Joshi","year":"2021","unstructured":"Joshi J, Raval A, Desai U et al (2021) EGFR Mutation Analysis in Non-small Cell Lung Carcinoma Patients: a Liquid Biopsy Approach. Indian J Clin Biochem 36(1):51\u201358. https:\/\/doi.org\/10.1007\/s12291-019-00864-7","journal-title":"Indian J Clin Biochem"},{"issue":"1","key":"8432_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ol.2012.950","volume":"5","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Oh SY, Kim WS et al (2013) Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncol Lett 5(1):271\u2013276. https:\/\/doi.org\/10.3892\/ol.2012.950","journal-title":"Oncol Lett"},{"issue":"2","key":"8432_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ab.2009.05.027","volume":"391","author":"S Dufort","year":"2009","unstructured":"Dufort S, Richard MJ, de Fraipont F (2009) Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues. Anal Biochem 391(2):166\u2013168. https:\/\/doi.org\/10.1016\/j.ab.2009.05.027","journal-title":"Anal Biochem"},{"issue":"4","key":"8432_CR23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","volume":"12","author":"AC Tsiatis","year":"2010","unstructured":"Tsiatis AC, Norris-Kirby A, Rich RG et al (2010) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12(4):425\u2013432. https:\/\/doi.org\/10.2353\/jmoldx.2010.090188","journal-title":"J Mol Diagn"},{"issue":"7","key":"8432_CR24","doi-asserted-by":"publisher","first-page":"740","DOI":"10.6004\/jnccn.2010.0056","volume":"8","author":"DS Ettinger","year":"2010","unstructured":"Ettinger DS, Akerley W, Bepler G et al (2010) Non-small cell lung cancer. J Natl Compr Canc Netw 8(7):740\u2013801. https:\/\/doi.org\/10.6004\/jnccn.2010.0056","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"8432_CR25","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/1759-7714.13577","volume":"11","author":"D Li","year":"2020","unstructured":"Li D, Ding L, Ran W et al (2020) Status of 10 targeted genes of non-small cell lung cancer in eastern China: a study of 884 patients based on NGS in a single institution. Thorac Cancer 11(9):2580\u20132589. https:\/\/doi.org\/10.1111\/1759-7714.13577","journal-title":"Thorac Cancer"},{"issue":"1","key":"8432_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.21037\/jtd.2017.12.68","volume":"10","author":"M Zhao","year":"2018","unstructured":"Zhao M, Zhan C, Li M et al (2018) Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 chinese patients with lung adenocarcinoma. J Thorac Dis 10(1):398\u2013407. https:\/\/doi.org\/10.21037\/jtd.2017.12.68","journal-title":"J Thorac Dis"},{"issue":"11","key":"8432_CR27","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/bjc.2014.210","volume":"110","author":"S Li","year":"2014","unstructured":"Li S, Li L, Zhu Y et al (2014) Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 chinese cohorts. Br J Cancer 110(11):2812\u20132820. https:\/\/doi.org\/10.1038\/bjc.2014.210","journal-title":"Br J Cancer"},{"key":"8432_CR28","doi-asserted-by":"publisher","first-page":"117955492211032","DOI":"10.1177\/11795549221103215","volume":"16","author":"R Liu","year":"2022","unstructured":"Liu R, Zhou J, Ling X (2022) Optimizing patient outcomes through sequential EGFR TKI treatment in asian patients with EGFR mutation-positive NSCLC. Clin Med Insights Oncol 16:11795549221103215. https:\/\/doi.org\/10.1177\/11795549221103215","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"8432_CR29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.athoracsur.2020.05.041","volume":"111","author":"K Suda","year":"2021","unstructured":"Suda K, Mitsudomi T, Shintani Y et al (2021) Clinical impacts of EGFR Mutation Status: analysis of 5780 surgically resected Lung Cancer cases. Ann Thorac Surg 111(1):269\u2013276. https:\/\/doi.org\/10.1016\/j.athoracsur.2020.05.041","journal-title":"Ann Thorac Surg"},{"issue":"15","key":"8432_CR30","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1200\/JCO.2005.04.8033","volume":"24","author":"CK Toh","year":"2006","unstructured":"Toh CK, Gao F, Lim WT et al (2006) Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 24(15):2245\u20132251. https:\/\/doi.org\/10.1200\/JCO.2005.04.8033","journal-title":"J Clin Oncol"},{"key":"8432_CR31","doi-asserted-by":"publisher","first-page":"31636","DOI":"10.1038\/srep31636","volume":"6","author":"Y Jin","year":"2016","unstructured":"Jin Y, Chen M, Yu X (2016) Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Sci Rep 6:31636. https:\/\/doi.org\/10.1038\/srep31636","journal-title":"Sci Rep"},{"issue":"3","key":"8432_CR32","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00595-013-0589-2","volume":"44","author":"T Ohba","year":"2014","unstructured":"Ohba T, Toyokawa G, Kometani T et al (2014) Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surg Today 44(3):478\u2013486. https:\/\/doi.org\/10.1007\/s00595-013-0589-2","journal-title":"Surg Today"},{"issue":"9","key":"8432_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00595-015-1295-z","volume":"46","author":"T Ohba","year":"2016","unstructured":"Ohba T, Toyokawa G, Osoegawa A et al (2016) Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma. Surg Today 46(9):1091\u20131098. https:\/\/doi.org\/10.1007\/s00595-015-1295-z","journal-title":"Surg Today"},{"issue":"3","key":"8432_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.athoracsur.2013.05.091","volume":"96","author":"B Izar","year":"2013","unstructured":"Izar B, Sequist L, Lee M et al (2013) The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg 96(3):962\u2013968. https:\/\/doi.org\/10.1016\/j.athoracsur.2013.05.091","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"8432_CR35","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ejca.2014.01.018","volume":"50","author":"CY Yang","year":"2014","unstructured":"Yang CY, Lin MW, Chang YL et al (2014) Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50(7):1361\u20131369. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.018","journal-title":"Eur J Cancer"},{"issue":"5","key":"8432_CR36","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1111\/ajco.12512","volume":"13","author":"T Nishii","year":"2017","unstructured":"Nishii T, Yokose T, Miyagi Y et al (2017) Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma. Asia Pac J Clin Oncol 13(5):e204\u2013e211. https:\/\/doi.org\/10.1111\/ajco.12512","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"8432_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12032-013-0771-9","volume":"31","author":"WS Liu","year":"2014","unstructured":"Liu WS, Zhao LJ, Pang QS et al (2014) Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol 31(1):771. https:\/\/doi.org\/10.1007\/s12032-013-0771-9","journal-title":"Med Oncol"},{"issue":"10","key":"8432_CR38","doi-asserted-by":"publisher","first-page":"e0186567","DOI":"10.1371\/journal.pone.0186567","volume":"12","author":"CY Lin","year":"2017","unstructured":"Lin CY, Wu YM, Hsieh MH et al (2017) Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma. PLoS ONE 12(10):e0186567. https:\/\/doi.org\/10.1371\/journal.pone.0186567","journal-title":"PLoS ONE"},{"issue":"12","key":"8432_CR39","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1097\/JTO.0b013e31826bb7b2","volume":"7","author":"SP D\u2019Angelo","year":"2012","unstructured":"D\u2019Angelo SP, Janjigian YY, Ahye N et al (2012) Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 7(12):1815\u20131822. https:\/\/doi.org\/10.1097\/JTO.0b013e31826bb7b2","journal-title":"J Thorac Oncol"},{"issue":"8","key":"8432_CR40","doi-asserted-by":"publisher","first-page":"e106053","DOI":"10.1371\/journal.pone.0106053","volume":"9","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang T, Zhang J et al (2014) Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis. PLoS ONE 9(8):e106053. https:\/\/doi.org\/10.1371\/journal.pone.0106053","journal-title":"PLoS ONE"},{"key":"8432_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5582","author":"C Long","year":"2023","unstructured":"Long C, Li K, Liu Z et al (2023) Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.5582","journal-title":"Cancer Med"},{"issue":"10","key":"8432_CR42","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bjc.2015.356","volume":"113","author":"FC Kuan","year":"2015","unstructured":"Kuan FC, Kuo LT, Chen MC et al (2015) Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. Br J Cancer 113(10):1519\u20131528. https:\/\/doi.org\/10.1038\/bjc.2015.356","journal-title":"Br J Cancer"},{"issue":"25","key":"8432_CR43","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2217\/fon-2019-0346","volume":"15","author":"MJ Hochmair","year":"2019","unstructured":"Hochmair MJ, Morabito A, Hao D et al (2019) Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol 15(25):2905\u20132914. https:\/\/doi.org\/10.2217\/fon-2019-0346","journal-title":"Future Oncol"},{"issue":"5","key":"8432_CR44","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/cas.12125","volume":"104","author":"K Furuyama","year":"2013","unstructured":"Furuyama K, Harada T, Iwama E et al (2013) Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors. Cancer Sci 104(5):584\u2013589. https:\/\/doi.org\/10.1111\/cas.12125","journal-title":"Cancer Sci"},{"issue":"9","key":"8432_CR45","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jtho.2017.05.018","volume":"12","author":"EE Ke","year":"2017","unstructured":"Ke EE, Zhou Q, Zhang QY et al (2017) A higher proportion of the EGFR T790M mutation may contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol 12(9):1368\u20131375. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.018","journal-title":"J Thorac Oncol"},{"key":"8432_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.07.007","volume":"101","author":"K Nosaki","year":"2016","unstructured":"Nosaki K, Satouchi M, Kurata T et al (2016) Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study. Lung Cancer 101:1\u20138. https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.007","journal-title":"Lung Cancer"},{"issue":"1","key":"8432_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-015-1776-3","volume":"124","author":"B Li","year":"2015","unstructured":"Li B, Sun SZ, Yang M et al (2015) The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma. J Neurooncol 124(1):79\u201385. https:\/\/doi.org\/10.1007\/s11060-015-1776-3","journal-title":"J Neurooncol"},{"issue":"2","key":"8432_CR48","doi-asserted-by":"publisher","first-page":"e0192161","DOI":"10.1371\/journal.pone.0192161","volume":"13","author":"WY Chang","year":"2018","unstructured":"Chang WY, Wu YL, Su PL et al (2018) The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. PLoS ONE 13(2):e0192161. https:\/\/doi.org\/10.1371\/journal.pone.0192161","journal-title":"PLoS ONE"},{"issue":"26","key":"8432_CR49","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Ahn MJ, Garassino MC et al (2018) CNS efficacy of Osimertinib in patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data from a Randomized Phase III Trial (AURA3). J Clin Oncol 36(26):2702\u20132709. https:\/\/doi.org\/10.1200\/JCO.2018.77.9363","journal-title":"J Clin Oncol"},{"issue":"12","key":"8432_CR50","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"C Grommes","year":"2011","unstructured":"Grommes C, Oxnard GR, Kris MG et al (2011) Pulsatile\u201d high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13(12):1364\u20131369. https:\/\/doi.org\/10.1093\/neuonc\/nor121","journal-title":"Neuro Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08432-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T20:33:06Z","timestamp":1684960386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08432-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["8432"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08432-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"13 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As it is a retrospective observational study, no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}}]}}